BioVie Inc BIVI

US Biotechnology

$1.61 ▼ -0.31% ($-0.01)

🎈 Low Float

Open $1.66

Prev Close $1.61

Day Range $1.58 – $1.75

52W Range $0.82 – $3.79

Market Cap $13.69M

Beta 0.81

EPS (TTM) $-3.15

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2014-01-14
Shares Out.	7,540,000
Website	bioviepharma.com/ ↗
Phone	17758883162
Employees	13
Revenue	$0
Gross Profit	$0
Net Income	-$5.6M
Free Cash Flow	-$19.0M
Total Assets	$14.3M
Total Liabilities	$4.0M
Equity	$10.3M

About BioVie Inc

BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

BioVie Inc is a publicly traded company under the ticker symbol BIVI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.